E224: The Diagnostic Room: The Financial Case Your CFO Actually Needs to See Before Approving Your AI Strategy

In this solo episode of AI For Pharma Growth, Dr Andree Bates tackles one of the biggest reasons pharma AI strategies stall: they are not presented in the financial language a CFO can approve.Dr Andree argues that the issue is rarely whether AI has value. The issue is that most organisations cannot quantify that value in a way that connects to business outcomes, baselines, investment priorities, timelines and return. Too often, teams arrive with pilots, use cases, vendor proposals and enthusiasm, but no financial model that can survive board-level scrutiny.With the patent cliff putting hundreds of billions in revenue at risk, AI is being positioned as a strategic lever across R&D, commercial, medical, regulatory and market access. But activity is not strategy. A use case that looks impressive in isolation may not be the one that moves the business most.This episode explains what a credible AI financial case needs to include: initiative-level modelling, realistic cost assumptions, adoption scenarios, redeployment of time and talent, technology cost changes, the cost of inaction, and sequencing. Dr Andree also explains why implementation order can change return, because some initiatives create the data, governance and organisational readiness needed for others to work.The core message is clear: AI strategy must be treated as a financial discipline, not just a technology ambition. If you cannot explain which AI initiatives matter most, why they come first, what return they should generate and when, you do not yet have the case your CFO needs.Topics CoveredWhy AI business cases often fail with CFOsThe difference between AI activity and AI strategyWhy pilot ROI is not enoughPatent cliff pressure and financial rigourComparing AI initiatives against business prioritiesRedeployment and real financial returnTechnology cost modellingThe cost of not actingWhy sequencing changes AI ROIEularis helps pharma and biotech leaders turn AI activity into board-defensible strategy and measurable commercial outcomes. If your organisation has plenty of AI in motion but very little that moves the commercial needle in a way the board can see, start with our 10-Day AI Diagnostic Sprint. It’s a focused diagnostic that surfaces what’s actually broken and what’s blocking results, before you invest in a larger strategy effort.The Sprint diagnoses the problem. The AI Strategic Blueprint that follows is where we build the board-defensible strategy and plan. Details at eularis.comIf this episode described your situation, send me a LinkedIn DM starting with ‘SENSECHECK’ and two things: the question you’re trying to answer internally, and what’s currently in flight. I’ll reply with what I’d need to see to turn that activity into a defensible plan, and the next step.About the PodcastAI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.Dr. Andree Bates LinkedIn | Facebook | X